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Background: Each year in Canada there are 5 million episodes of acute gastroenteritis (AGE) with up to 70 %
attributed to an unidentified pathogen. Moreover, 90 % of individuals with AGE do not seek care when ill, thus,
burden of disease estimates are limited by under-diagnosing and under-reporting. Further, little is known about the
pathogens causing AGE as the majority of episodes are attributed to an “unidentified” etiology. Our team has two
main objectives: 1) to improve health through enhanced enteric pathogen identification; 2) to develop economic
models incorporating pathogen burden and societal preferences to inform enteric vaccine decision making.
Methods/Design: This project involves multiple stages: 1) Molecular microbiology experts will participate in a
modified Delphi process designed to define criteria to aid in interpreting positive molecular enteric pathogen test
results. 2) Clinical data and specimens will be collected from children aged 0–18 years, with vomiting and/or
diarrhea who seek medical care in emergency departments, primary care clinics and from those who contact a
provincial medical advice line but who do not seek care. Samples to be collected will include stool, rectal swabs
(N = 2), and an oral swab. Specimens will be tested employing 1) stool culture; 2) in-house multiplex (N = 5) viral
polymerase chain reaction (PCR) panel; and 3) multi-target (N = 15) PCR commercially available array. All participants
will have follow-up data collected 14 days later to enable calculation of a Modified Vesikari Scale score and a
Burden of Disease Index. Specimens will also be collected from asymptomatic children during their well child
vaccination visits to a provincial public health clinic. Following the completion of the initial phases, discrete choice
experiments will be conducted to enable a better understanding of societal preferences for diagnostic testing and
vaccine policy. All of the results obtained will be integrated into economic models.
Discussion: This study is collecting novel samples (e.g., oral swabs) from previously untested groups of children
(e.g., those not seeking medical care) which are then undergoing extensive molecular testing to shed a new
perspective on the epidemiology of AGE. The knowledge gained will provide the broadest understanding of the
epidemiology of vomiting and diarrhea of children to date.
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Current epidemiologic knowledge of acute gastroenter-
itis (AGE) pathogens is limited to subsets of children
with select clinical presentations and by tests capable ofFig. 1 Pathway to Innovationidentifying only a limited number of pathogens. APPE-
TITE (The Alberta Provincial Pediatric EnTeric Infec-
tion TEam) has built a pathway to innovation (Fig. 1)
that strives to develop a better understanding of the
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in specimen collection and testing. We will move from:
1) stool collection (usually at home, if done at all, and
returned to facility) to point of care swabs [oral/rectal –
by health-care provider (HCP)]; 2) multiple labour inten-
sive tests (e.g., culture, microscopy, electron microscopy)
with poor sensitivity to a single device, which employs
polymerase chain reaction (PCR) technology to target
multiple pathogens with high sensitivity and has the
potential to be integrated into point of care testing
technology [1–3].
Our proposal includes three activities that are chrono-
logically inter-woven and interconnected to maximize
the conduct of integrated knowledge translation (iKT).
The activities are: Activity 1 - burden of disease as-
sessment through broad population surveillance with
expanded data collection; Activity 2 - enhanced patho-
gen identification through improved specimen collec-
tion (oral and rectal swabs) and molecular (PCR)
diagnostic technology; and Activity 3 – preference
elicitation and economic modeling which will be
planned, and interpreted alongside our decision-makers.
Activity #3 will be conducted in conjunction with the
data and knowledge gained from Activities #1 and 2.
Multi-directional knowledge exchange will be used to
address the following key questions identified by our
end-users: Theme 1) Do we add an enteric vaccine to
Alberta’s vaccination schedule, and when (now for rota-
virus; later for norovirus)? If so, how do we optimize up-
take?; Theme 2) Do we change policy and employ swabs
in Alberta’s laboratories that process specimens? Do we
integrate multi-analyte, non-culture PCR technology
into all or some of our laboratories? What would the
cost be of such an approach?
APPETITE’s research plan was designed through a
series of in-person meetings, teleconferences, and an
in-person all day gathering of investigators in Calgary
(October 28, 2013). APPETITE’s agenda addresses a
high-impact, high-needs problem while balancing the
needs of our end-user partners. The agenda directly
tackles key health policy issues - child health, infectious
disease, health promotion, vulnerable populations -
identified by Alberta’s Health Research and Innovation
Strategy [4], and Alberta’s Maternal, Newborn, Child &
Youth Health Emerging Clinical Network’s [5] research
priorities (i.e., rotavirus immunization).
Suggestions from the Alberta Children’s Hospital
(ACH) Family Advisory Committee (November 7, 2013),
and a HCP survey (November 2013) were integrated into
our research plan. Preliminary analysis (n = 90) provided
the following insights: 1) 53 % believe caregivers would
be interested in adding an enteric vaccine; 2) 81 % be-
lieve an additional requirement should include cost-
effectiveness; 3) only 9 % believe that current methodsof stool sample collection are easy and convenient; and
4) 82 % believe that specimen submission would be im-
proved if rectal swab samples were employed.
Knowledge gaps
We test for too few pathogens in too few patients and thus
do not understand the true impact of AGE
1. Unknown Epidemiology of Disease (Fig. 2):
Although 90 % of affected individuals do not seek
medical care, they account for over 70 % of the total
cost of illness (due to missed employment) [6]. Of
those who do seek care, only 6 % submit stool
samples [7]. Even then, only diarrheal specimens are
tested and most often for bacteria and parasites
(Table 1), and such agents cause only 10-15 % of
disease. Over 60 % of pediatric stool cultures in
Calgary are from hospitalized children who
represent <1 % of the pediatric population with
AGE [8, 9]. In a survey of 1000 randomly identified
patients at 31 Canadian emergency departments
(ED), vomiting was the most common reason
children were brought for care [TRanslating
Emergency Knowledge for Kids (TREKK);
http://trekk.ca/]. [10]. However, because of
technological limitations children with isolated
vomiting (i.e., without diarrhea), rarely have
samples tested to identify an infectious etiology. Hence
diarrheagenic pathogens are over-represented among
causes of enteric events. Our lack of true pathogen-
specific burden of disease knowledge impairs our
ability to deliver evidence-based prevention strategies.
2. Pathogen Identification
Enhanced enteric disease diagnostics are needed as
1) there are significant public health implications; 2)
the potential severity of disease is significant (2–3 %
of those affected develop persistent health problems)
[11]; and 3) timely treatment may be crucial.
Examples of the importance of pathogen
identification include: 1) Verotoxin-producing E. coli
(synonymous with Shiga-toxin producing E. coli)
[12], although uncommon, can cause hemolytic
uremic syndrome, the most common cause of acute
renal failure in children [13, 14]. The lifetime cost/case
is >2.8 million Euro [15]. Current testing algorithms
entail sending patients home to collect and return
stool specimens. If returned, often 1 – 2 days later,
such specimens are processed employing culture
techniques, which further delay pathogen identification
[16]. Point of care collection (i.e., rectal swab) followed
by rapid molecular identification (e.g., PCR) would
enable the early provision of therapies to reduce
the severity of renal failure [17–19]; 2) The
identification of norovirus, which causes 800
Fig. 2 Overall societal burden of disease in relation to those who undergo testing. The image portrays the total burden of acute gastroenteritis
(green), in relation to the smaller subset that have diarrhea (only group eligible for testing; purple). This is followed by the much smaller
proportion who actually seek medical care (yellow) and lastly by the tiny proportion who actually undergo testing (note, even when tested,
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immunotherapy administration to high-risk
individuals [21]; 3) From a public health perspective,
a rapid assessment tool will assist in separating
epidemic episodes of mild AGE from public health
emergencies [22].
3. Patient Preferences and Cost Effectiveness
Little is known about preferences of patients and
caregivers in relation to enteric vaccines. Economics
also play a role in decision-making processes because
optimizing the distribution of limited health-care
resources is mandatory [23]. In accordance with
recommendation in the 2013 report from the Public
Health Agency of Canada [11], we conducted focus
group meetings with the ACH Family Advisory
Committee. The following themes emerged fromble 1 Results from routine pediatric laboratory testing
algary Laboratory Services); 01/01/2012 – 31/12/2012
lgary Laboratory Services # Performed % Positive
ral testing (Rotavirus only) 1541 10 %
cterial testing 3472 6 %
rasite testing 3230 9 %
ostridium difficile testing 2071 12 %
tals 10,314 8.7 %
ruses, responsible for 70–90 % of AGE, were only identified in 10 % of
mples. The most common tests – bacterial culture and parasite microscopy,
d the lowest rates of positivitythese discussions: 1) need to focus on introducing
“critical” vaccines; 2) a vaccine now (i.e., rotavirus)
may decrease future vaccine uptake (i.e., norovirus);
and 3) importance of comparing public health
impact of rotavirus vaccine to other (non-AGE)
potential interventions that could be implemented.
However, since studies to date have not included
children with isolated vomiting, which is commonly
seen with norovirus [24, 25] and those not seeking
care, the economic models employed to guide
vaccine policy, and outline the opportunity costs of
such policies, have employed data with significant
limitations [26–28].Methods/Design
Overview
This phase of our team’s study focuses on developing an
adaptation-friendly reproducible model of infectious dis-
ease epidemiology assessment. It is designed to capture
a comprehensive clinical picture of AGE (i.e., those with
isolated vomiting, isolated diarrhea, and combined) in
diverse settings (e.g., home, primary care, ED). Evaluat-
ing etiology in an unbiased manner has been identified
as priority by key decision-makers to 1) identify the
most common pathogens (viral, bacterial, parasitic); 2)
associate each pathogen with illness severity (all set-
tings); and 3) enable the construction of economic
models to inform health-care investment decisions.
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We do not know which pathogen(s) are most responsible
for AGE in terms of frequency or severity because the full
community-based spectrum and extent of AGE (which is
8 times more frequent than physician visits) [29] has not
been performed in recent decades. The frequency of AGE
and its impact in the community is reflected in Health
Link Alberta (provincial telephone help-line) data: 39 % of
all pediatric calls are because of AGE and 67 % result in a
recommendation for care at home [courtesy Alberta
Health (AH)]. Although viral infections cause 75–90 % of
infectious gastroenteritis, current testing approaches iden-
tify a pathogen in only 10 % of specimens (Fig. 3) because
testing focuses on rotavirus which has been viewed as the
most important pathogen [30]. Consequently rotavirus
has been the target of Canadian surveillance efforts [31]
which collect data on hospitalized children and select ED
populations. In light of this knowledge gap, the Office of
the Chief Medical Officer of Health of Alberta has added
rotavirus to the notifiable diseases list effective January
2014. However, standard clinical testing will remain re-
stricted to individuals with diarrhea presenting for ED
care and those requiring hospitalization. In the currentFig. 3 Current testing compared with multi-analyte array. Clinical testing (r
are ordered). The Luminex GPP multi-analyte array we propose to use (left)
comprehensive test panel. The results will delineate the epidemiology of A
majority of viral pathogens are not identified under current testing algorith
laboratories in the provincestate, the true burden of disease (e.g., isolated vomiting;
never tested) will remain unknown as will the prevalence
of other pathogens, especially norovirus [32].
Alberta is an outstanding setting in which to study the
pathogen-specific burden of disease because 1) rotavirus
vaccine has not been introduced in this province so the
natural spectrum of illness exists; 2) vaccines are admin-
istered at public health clinics thereby providing a
wealth of population and patient specific vaccine data;
and 3) our team will have access to clinical outcome and
exposure data related to notifiable enteric pathogens.
The need to study AGE epidemiology where rotavirus
remains prevalent is important. In U.S. where rotavirus
vaccination is common, norovirus is the most frequent
cause of diarrheal disease in children [33–38]. However,
the relative burden of disease (rotavirus vs. norovirus) in
the absence of rotavirus vaccine is unknown.
Project #1: case definitions
Case definitions for illnesses likely to be caused by
each candidate pathogen will be defined a priori. This
work will employ a modified Delphi technique consist-
ing of anonymous questionnaires and a face-to-faceight) is limited to a narrow group of pathogens (unless multiple tests
employs a single stool or swab (rectal/oral) specimen to perform a
GE in Alberta (Activity #2; left). Note - VTEC (non O157), ETEC, and the
m (right). Note - Edwardsiella is only routinely tested for in select
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tive tests represent true “disease” (e.g., C. difficile in
children <1 year rarely causes disease) [39].
Indicator identification and development
For the clinical features selected by the advisory panel, a
review of the literature will be conducted to identify 1)
existing case definitions 2) practice guidelines, and high
quality systematic reviews that could be used to inform
the creation of case definitions and 3) infections for
which no guidelines or evidence exists.
Existing case definitions
Existing case definitions for the selected pathogens will
be identified through a search of the literature on enteric
infections in children. Search terms will include those
corresponding to clinical features and case definitions
combined with terms describing each of the enteric
pathogens. Examples of search terms will include: case
definition, clinical feature, specific pathogen and infection/
carrier. An initial list of existing case definitions and
references will be created. Case definitions will be pre-
sented by pathogen, infection status (carrier/”infection”),
and diagnostic test modality.
Existing case definitions for the selected conditions
will also be identified by searching websites that focus
on enteric infectious diseases and specific pathogens. Ex-
amples of websites include the Infectious Disease Society
of America.
Advisory panel
An advisory panel consisting of approximately 20 deci-
sion makers and stakeholders will be created to select
variables to be included in our case definitions. The
Delphi technique, a structured interactive method involv-
ing repetitive administration of anonymous question-
naires, will be used [40]. The advisory panel will consist of
pediatricians, pediatric emergency medicine physicians, in-
fectious disease experts, medical microbiologists, and ex-
perts in virology and laboratory medicine. Participants will
be identified by APPETITE’s International Scientific Ad-
visory Committee and Strategic Advisory Committee and
will be recognized experts in this field and will be repre-
sentative of the perspectives held in Canada, the USA and
Europe. Representatives from stakeholder organizations
will be contacted and asked to provide the names of indi-
viduals with an interest in pediatrics, infectious disease
and enteric infections. The panel will then be chosen from
the master list of experts by the research team. Criteria
for selection will include: interest or expertise in enteric
infections in the pediatric population, experience in in-
fectious diseases, geographic representation across
Canada, practice diversity, and balance between indi-
viduals with clinical expertise and those with laboratoryexpertise. Selected panel members will receive a written
invitation to participate in this project that will outline
the goals of the project, their responsibilities and the
timeline. Written invitations will be followed by a tele-
phone conversation with one of the study investigators.
A description of the goals of the research project, as
well as a summary of the literature review including the
full list of existing and newly developed evidence-based,
case definitions will be sent. The case definitions will be
organized by pathogen, specimen type (rectal swab, oral
swab, bulk stool), and diagnostic test employed.
The advisory panel will be sent the candidate list of vari-
ables to be considered. They will then be asked to suggest
other clinical features that might assist in discriminating
“infection” from the “carrier” state. A complete list of all
candidate clinical features will then be assembled. A priori-
tized list of clinical features will then be generated through
a multistage survey process.
In the first stage of the survey panelists will be asked to
rate each clinical feature on three different criteria: 1) Im-
portance/Impact – to what degree is this clinical feature
important when discriminating infection from carrier
state. 2) Prevalence – how frequently is this clinical feature
present in those usually determined to have “disease”. 3)
Validity – how solid is the scientific or professional con-
sensus to support a link between the clinical feature and
the presence of “disease”. Panelists will be asked to rate
each clinical feature on all three criteria on a scale from 1
(strongly disagree) to 9 (strongly agree).
Any clinical feature rated 1, 2 or 3 for all of the 3 criteria
by all panelists will be removed from further consider-
ation. Any clinical feature rated 7, 8 or 9 by all panelists
for all 3 criteria will be retained for further case definition
development and removed from the next survey round.
The remaining clinical features will be included in a
new survey for the second stage of the Delphi Process.
The second survey will be individualized for each panel
member and for each clinical feature and will include
the member’s prior rating, the overall panel median rat-
ing and the range of ratings assigned on each of the
clinical features. The panelists will then be asked to re-
rate each clinical feature on the same three criteria.
Each panelist’s ratings for the three criteria will be
added. Conditions with mean scores ≥7 by 2/3 of panelists
will included in the final list of clinical features used to
define “disease”.
The advisory panel will then have a face-to-face meet-
ing. At the meeting, the panelists will review anon-
ymized ratings of all the clinical features. Panelists will
be asked to refine highly scored clinical features and to
discuss low scoring and indeterminate clinical features.
Panelists will also be given the opportunity to suggest
clinical features for pathogens with no existing case defi-
nitions and to identify significant gaps where more
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meeting panelists will be asked to independently re-rate
each clinical feature on the same four criteria. Clinical
features with mean scores ≥7 across all four criteria by
2/3 of panelists will be included in the final list of
indicators.
Project #2: specimen collection/testing
We will collect specimens (oral and rectal swabs plus
stool) from children spanning the spectrum of severity
and clinical presentations (i.e., isolated diarrhea, diar-
rhea and vomiting, isolated vomiting). A multi-year
evaluation will allow us to capture the seasonal vari-
ation of clinical presentation and intensity of pathogen
activity [41, 42].
Objectives
The project will achieve the following objectives:
1) Determine if swab specimens are adequate (or even
preferred) alternatives to stool sample collection and
testing, stratified by clinical presentation, for viral,
bacterial, parasitic and C. difficile.
2) Determine the test characteristics of the multi-analyte
assay employing all three sampling methods, in
comparison with reference standards (i.e., stool
culture), and work with end-users [Calgary
Laboratory Services (CLS), Provincial Laboratory
for Public Health (ProvLab)] to clarify its role in
the Alberta context.
3) Determine the genotype profiles of bacteria and
viruses in relation to vaccines and epidemic strains.
Note – oral swabs will only be analyzed in the context
of viral pathogens (no expectation to identify bacteria,
parasites).
Outcome measures
Primary outcome: The proportion of all cases caused
by the most common pathogen (likely rotavirus or
norovirus).
Secondary outcome: The ‘burden of disease index’
which is created by multiplying 1) frequency of disease
and 2) mean Modified Vesikari Scale score to provide
the burden in relation to setting and resource use.
Study population
Inclusion Criteria: Eligible children will:
1. Be aged 0–17.99 years of age
2. Have AGE defined by the presence of a minimum of
three episodes of vomiting OR diarrhea in the
preceding 24 h and < 7 days of symptoms [43]
(Medical Care)Exclusion Criteria: Children with any of the following
will not be eligible:
1. Previously enrolled within the last 14 days (Medical
Care)
2. Previously enrolled in the study (Self-Care)
3. Unavailable for follow-up
4. Chief complaint likely related to acute infection (i.e.,
presence of any of the following: vomiting, diarrhea,
fever, running nose, and/or cough) (Self-Care)
5. History of depression, bipolar disorder,
schizophrenia, or other significant underlying
psychiatric illness
6. History of low white blood cells (neutrophils < 1000)
7. The child needing emergent care from the clinical
team
Settings
Participants will be indentified from two cohorts:
1. Medical Care (N = 2250): To reflect a broad range of
severity, children will be recruited from EDs
including Alberta’s two pediatric EDs (Calgary and
Edmonton). Both are members of Pediatric
Emergency Research Canada (PERC) which has
endorsed this study. Specimens (stool, oral and
rectal swabs) will be obtained from children during
the ED visit (if consent and assent are obtained as
appropriate-Appendix 5). Home stool collection will
be performed for those unable to provide a sample
while in the ED and will be achieved by providing
families with collection kits, instructions for specimen
handling and preparation and a number to call to
arrange for specimen retrieval and transport for
processing (Appendix 5) [44].
2. Self-Care (N = 2250): This group will illuminate the
burden of disease amongst children whose families
do not physically seek evaluation. This cohort
represents the greatest burden of disease,
particularly in economic terms (i.e., caregiver lost
productivity). We will recruit (i.e., pre-enrol) these
participants while asymptomatic to enable them to
participate when they experience an episode of AGE
(defined as ≥3 episodes of vomiting or diarrhea in a
24 h period) [43]. Based on available data, 90 % of
such events will not result in medical care [45] –
such visits will define our self-care cohort. Should
medical care be sought (10 % of this group), they
will be re-assigned to the medical care cohort. At
the index visit, children will have rectal and oral
swabs performed to enable the generation of baseline
data to understand the carrier rate in the general
population. This opportunity will also serve as a
teaching moment such that caregivers will
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rectal swabs, and stool) at home once their child
becomes ill. Prior to leaving the ED, they will be
provided with collection kits, instructions for
specimen handling and a number to call to arrange
for specimen retrieval and transport for processing
(to optimize return rate) [44].
In addition children will be recruited through Health-
Link Alberta. This is a telephone resource, which is ac-
cessible to all Albertans, that provides guidance on the
management of common medical conditions. For true
emergencies, callers are told to call 911. For very minor
conditions they are given guidance and instructed to
manage the client at home. For those with symptoms of
unclear importance they are often instructed to seek
medical care. HealthLink AB has agreed to provide, with
caregiver permission, the contact information related to
phone calls of children aged < 18 years with AGE who
are instructed to be cared for at home. The APPETITE
team member will then follow-up with the caregiver/
child to seek consent/assent for participation. This can
be done either 1) verbally by phone; or 2) electronically
with the consent/assent forms downloaded from the
study website (www.gotgastro.ca) and then returned to
our team electronically. Once consent is obtained the
study sample collection packets and instructions will be
emailed to the client/caregiver and they will be asked to
complete the data collection forms.
The medical care and self-care cohorts will have
clinical data collected:
1) In person or electronically/telephone on the day the
specimens are provided/collected (Appendix 8).
2) 14 days after initial specimen collection (Appendix
9). This approach will enable us to collect outcome
data to quantify illness severity employing the
Modified Vesikari Scale score. This validated score
[46, 47] is based on symptoms and therapy provided
and is designed for use in AGE of unspecified
etiology. Additional data collected will include risk
factors for infection and severe disease, expenditures
and quality of life.
Experimental maneuvers – medical care cohort
Patients will be assessed and treated by ED staff with-
out any regard to this study. Stool specimen testing will
continue as per standard of care at all participating
sites. Once the inclusion criteria are confirmed and
parental consent is obtained (and child assent when ap-
propriate) an enrollment ID number will be assigned.
Research ethics board approval was obtained for re-
cruitment and specimen collection from both the Con-
joint Health Research Ethics Board of the University ofCalgary, and the Health Research Ethics Board of the
University of Alberta.
Index interview
Parents will be asked to participate in a standardized
5 min survey administered by study personnel. The sur-
vey will collect descriptive data regarding gastroenteritis
symptoms, childcare arrangements, parental work data,
medical treatment sought during the child’s illness, and
personal medical history. Those enrolled in an ED will
directly enter the information into an iPAD device.
Specimen collection
We will collect four specimens (2 rectal swabs, 1 oral
swab, and a stool sample) from each enrolled child. Ap-
proximately 750 children will be enrolled annually from
our medical care cohort. Oral and rectal swabs will be
performed prior to departure from the point of care
using a flocked rectal swab (FLOQSwab, Copan Italia,
Brescia, Italy). Stool will also be collected prior to de-
parture. If a specimen is not provided prior to departure,
we will provide caregivers with specimen collection con-
tainers and contact information for a courier service that
will retrieve the sample. After cultures are performed, all
swabs and stool specimens will be frozen at −70 °C for
future testing which will be performed in batches.
Follow-up
At the index visit, caregivers will be asked their preferred
method of communication – electronic (i.e., email survey)
versus telephone. 14 days after enrollment, a standardized
script or survey/data collection form will be employed to
conduct follow-up. This would be performed using a se-
cure RedCAP data system to minimize time required and
transcription errors. If phone is opted for, the caller will
enquire about ongoing symptoms, medical evaluations,
treatments, child care and work absenteeism, and side ef-
fects. Detailed questioning will follow positive responses.
The survey will employ advanced logic to enhance ease of
use. Electronic surveys will be e-mailed daily (maximum
of 3 times) until a survey is completed. If the caregiver
does not complete the electronic survey after 3 days, tele-
phone follow-up will be performed. Protocols will be de-
veloped to deal with caregiver questions in accordance
with institutional requirements.
All standardized surveys employed in this study consist
of a series of single-and multiple-select closed-ended items
allowing for the selection of a residual “other” category. In
cases in which the respondent feels that his or her re-
sponse does not correspond to one of those already listed
(ie. he/she selects “other”), the respondent will be asked to
elaborate on his or her answer in full text.
In order to optimize follow-up the following data is
collected at the initial point of contact: home, cellular,
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address. If phone follow-up is performed, we will call
all numbers provided at least once daily over 3 days
(maximum 5 attempts).
Specimen testing
In Year #1, all stool and rectal swab specimens [48, 49]
will be analyzed employing the following:
1) RT-PCR 5- target ‘in-house’ virus panel (adenovirus,
astrovirus, norovirus, rotavirus, sapovirus) [29];
2) multi-analyte assay [Luminex xTAG®
Gastrointestinal Pathogen Panel (GPP)]
3) standard bacterial culture
The Luminex GPP is an FDA and Health Canada ap-
proved, qualitative bead-based multiplexed molecular
diagnostic test that simultaneously identifies AGE caus-
ing viral, bacterial and parasitic pathogens. It has excel-
lent test characteristics when stool97,125 and rectal
swabs100,104 are employed - sensitivity >94 %, specificity
>98 % [50, 51]. Moreover, 65 % of pathogens identified
by the Luminex GPP remain unidentified when current
laboratory procedures are followed (i.e., physician must
suspect and order the appropriate pathogen specific test)
[50]. We will explore the use of the Luminex GPP to
identify viral targets from oral swabs which will undergo
confirmatory analysis via our ‘in-house’, RT-PCR, 5-
target viral panel. Employing Plan-Do-Study-Act cycles
we will modify our protocols (collection methods, swab
types, transport media, nucleic acid extraction) based on
results. Pathogen detection accuracy will be compared,
as appropriate, between the varying specimen collection
methods. The ‘best’ (accurate and convenient) specimen
type for testing will be identified. Once optimal speci-
men collection type and analysis methods have been de-
termined, subsequent testing will be streamlined.
Because monitoring for genetic and antigenic changes in
pathogens is crucial for viruses [52], specimens testing posi-
tive for rotavirus will be analyzed for G typing (VP7) and P
typing (VP4) using nested RT-PCR [53]. Those positive for
norovirus will be typed by DNA sequencing [52, 54]. Typ-
ing of bacterial targets will be performed, as appropriate,
using standard methodologies [55] to evaluate the ability of
our surveillance and comprehensive diagnostic approach to
discover outbreaks not identified by traditional approaches.
Experimental maneuvers – self care cohort
Screening, consent and the index interview will occur as
per the medical cohort.
Specimen collection
We will collect three specimens (2 rectal swabs, 1 oral
swab) from each enrolled child during the index visit.Approximately 750 children will be enrolled annually
from our self- care cohort. Oral and rectal swabs will be
performed prior to departure from the point of care
using a flocked rectal swab (FLOQSwab, Copan Italia,
Brescia, Italy). After a culture is performed, all swabs
will be frozen at −70 °C for future testing which will be
performed in batches.
Repeat specimens
At the index visit, caregivers will be provided with speci-
men collection containers, and instructions on sampling
to be repeated when their child does become sick. They
will be instructed to contact a research team member
should their child have ≥ 3 diarrheal or vomiting epi-
sodes in a 24 h period. This contact will initiate a call to
a courier service to conduct specimen retrieval along
with the e-mailing (or telephone completion) of the
baseline illness survey. If the caregiver does not contact
a team member, follow-up reminders will occur three
and/or six months following the index visit.
Follow-up and specimen testing will occur as per the
medical care cohort.
Sample size
We anticipate that rotavirus and norovirus will each be
present in ~20 % of cases. All other viruses combined
will be identified in ~20 % of cases; bacteria may be
present in 10 %. Thus, a pathogen will be identified in
60 – 70 % of participants. Each cohort (medical care &
self-care) will require 2250 (4500 in total) participants
assuming a point estimate of 20 % for the most frequent
pathogen (closest to point of most uncertainty to ensure
accurate estimates for less frequent ones) and a desire
for the 95 % confidence interval to be ≤ ±2 %. The preva-
lence of disease attributable to each pathogen will be
stratified by zone, potential risk groups (e.g., aboriginal,
co-morbidity, age, socioeconomic status) [43], exposures,
season, enrollment location, symptoms, severity, site of
recruitment, and antibiotic use. 4500 cases (and ~3150
containing at least one of the pathogens tested in this
study) will allow for a minimum of 10 cases of AGE for
each stratification covariate and thus extensive regres-
sion modeling. Since the primary outcome is based on
point-of-care rectal swab performance, compliance is a
potential concern for the self-care group. Recruitment
for the later will continue until specimens are received
from the required number of participants (N = 2250).
Duplicate samples <14 days from the same individual
will be removed to provide case-based data
Clinical features and outcomes will be correlated with
microbiologic findings. Age and sex-adjusted pathogen
specific prevalence and severity data will be calculated
and compared for all targets. Seasonality and geographic
distribution of each pathogen over time will be analyzed.
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Results will be analyzed bi-weekly, and the formats and
fields will be tailored to end-user needs. Recruitment
strategies will be modified in real-time based on success
(e.g., add/drop clinics, study promotion). Education tar-
geting participating families (e.g., information sheet, hy-
dration, hand hygiene, transmission) will be central to
our research-practice loop and will be refined based on
accrued data. Through our knowledge/end-user collabo-
rators, and utilizing the communication and reporting
chains present within their respective organizations
(primary care network leaders, pediatric ED end-users,
informatics, public health officers) we will share and
exchange findings to integrate results immediately to
assist with unrecognized outbreaks, pathogen cluster-
ing, severe disease and complications. We will maintain
bi-annual dialogue with our partner parent group to
modify our data collection and aims. There will be on-
going discussion of our results at network meetings
[PERC, TREKK, National Advisory Committee on
Immunization (NACI), medical officers of health, Al-
berta Health Services (AHS), AH] and immediate im-
provements in health-care delivery could result through
early implementation of novel sampling and testing
methods or by linking of ED physician and nurse staffing
to weekly APPETITE data.
Discussion
Governance
APPETITE has identified the need for a well designed
governance structure and research management mech-
anism. The governance model is designed to enhance
cross-sectoral collaborations and partnerships between
academia, industry and the applied healthcare setting.
The entities within the model create a framework
whereby APPETITE leaders are challenged with rigorous
internal checks and balances on research accountability,
quality, and productivity. The governance structure is
comprised of the following groups:
Strategic Advisory Committee (SAC)
Advises the APPETITE Executive Committee on the
overarching plans and goals at a high level (e.g., major
projects, activities, future funding, business model). The
SAC is comprised of representation from APPETITE’s
provincial [AH, AHS, Alberta Office of Chief Medical
Officer of Health, First Nations Inuit health Branch,
CLS, Clinical Informatics – AH, ProvLab Alberta), univer-
sities (University of Calgary – Alberta Children’s Hospital
Research Institute; University of Alberta – Women and
Children’s Health Research Institute), and community
stakeholders (Alberta Children’s Hospital Parent Advisory
Committee). APPETITE’s Executive team will seek advice
from its SAC on dispute resolution for high-level issues.International Scientific Advisory Committee (ISAC)
This group includes experts in enteric bacteria (Dr. Claire
Jenkins, Public Health England), diagnostic microbiology
(Dr. Carey-Ann Burnham, Washington University), trans-
lational research (Dr. Eileen Klein, Seattle Children’s
Hospital), emerging topics in gastrointestinal research (Dr.
Phil Sherman – Director, Canadian Institutes of Health
Research, Institute of Nutrition Metabolism and Diabetes),
viral gastroenteritis (Dr. Jon Gentsch, Centers for Disease
Control and Prevention), virology [Dr. Marion Koopmans,
National Institute of Public health (Netherlands)] They
are also joined by Dr. Bill Ghali who has expertise in
leading large multi-disciplinary research teams within
the University of Calgary (U of C). They will serve as
strategic and scientific advisors to APPETITE’s research
programs and collaborating members. APPETITE will
host each ISAC member as visiting professors for pe-
riods of up to 1 week, during which time they will advise
in real-time on APPETITE activities, and specific pro-
jects, give local teaching/training rounds and will meet
with trainees.
APPETITE executive
Composed of APPETITE’s Lead (Dr. Freedman), Co-
Leads (Drs. Lee, Louie, Pang), and the health economic
activity Co-Lead (Dr. Currie), the executive committee
meets weekly. Its members are accountable for the core
decision-making of all programs, ensuring completeness
of agency reporting, human resource and financial mat-
ters, keeping all activities on track, and updating team
members and relevant end-users as required.
Future directions
Our comprehensive and extensive dataset will contain
the necessary information to engage in deep, evidence-
informed, discussions regarding policy change with our
partner decision-makers at Alberta’s laboratories and the
Office of the Chief Medical Officer of Health. These dis-
cussions will determine diagnostic testing, vaccine, and
surveillance policy in Alberta for years to come, thereby
optimizing health at individual and societal levels. APPE-
TITE’s data and specimen repository will be employed
to conduct the next steps in PCR-based, point of care
diagnostics and norovirus vaccine research. Academia
and industry partners will work to develop: 1) an oral
viral pathogen panel; and 2) simplified point-of-care
diagnostic technology [2, 3, 56] to enable use in remote
communities and in low and middle income countries to
reduce AGE mortality [57].
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